Leadership Team
Driving Scientific and Business Excellence
Guiding innovation at the intersection of cutting-edge science and strategic business development to bring transformative therapies to patients worldwide.
Meet Our Executive Team
Our executives lead Dasher Neuroscience with deep expertise in drug discovery, development, and business strategy.
Tong-Ho Lin
Chairman
With 40+ years of experience in the biopharmaceutical industry, Mr. Lin excels in business operations and R&D. Formerly Chairman of Lotus Pharma, he oversaw its IPO and transformation into an international generic drug manufacturer, and now a key global base for Alvogen. In 2016, he founded Alar Pharma and led its IPO and successful licensing of new drugs. Leveraging his governance expertise, Mr. Lin guides Dasher Neuroscience Inc. in formulating and strategically planning products for early regulatory approval.
Yufeng Jane Tseng
CEO/Founder
Prof. Tseng, an experienced medicinal chemist and bioinformatician, served as an IRTA Research Fellow at the National Center for Biotechnology Information, NIH in the United States. Since 2014, she’s been a professor at National Taiwan University, specializing in computational chemistry and AI-assisted drug design. In 2019, as one of Dasher Neuroscience’s founders, Prof. Tseng was instrumental in licensing YA-101 and other CNS compounds to the company. With vast experience in drug discovery and development, Prof. Tseng has established strong networks with hospitals and CROs, secured intellectual property rights, and gained approval for candidate drugs in anti-thrombotic, anti-cancer, anti-neuropathic pain, and CNS compounds, contributing significantly to Dasher Neuroscience Inc.’s successful research projects.
Meet Our Advisors
Our advisors bring scientific, clinical, and regulatory expertise to advance innovative therapies.
Po Shun Lee MD
Medical Advisor
Dr. Lee, boasting more than 25 years of industry expertise, has assumed pivotal roles at distinguished organizations including Vertex Pharmaceuticals, Proteostasis Therapeutics, Novartis Institutes, and others. Simultaneously, he serves as a physician at Tufts Medical Center, channeling his extensive knowledge into the global biotech industry for new drug development and pharmaceutical strategy. Dr. Lee is actively engaged in guiding Dasher Neuroscience Inc. through the intricacies of designing and executing clinical trials, offering invaluable insights for the development of robust clinical trial protocols.
Michael Taylor PhD
Toxicologist Consultant
Dr. Taylor brings over 40 years of expertise in preclinical safety assessment (toxicology, pharmacology, DMPK) in pharmaceuticals. His broad experience covers various therapeutic areas, administration routes, and consulting services such as IND/registration planning, research design, and regulatory interactions. He effectively supports Dasher Neuroscience Inc. in formulating high-value IND strategies, assessing non-clinical data, and optimizing time and cost efficiency.
Lisa Kang
Clinical Consultant
Lisa is a chemist trained at the University of North Carolina Chapel Hill, with additional training in clinical biostatistics from Tulane University and Harvard Medical School. With over 20 years of experience in the biomedical pharmaceutical industry, she has worked with or contributed to various well-known international pharmaceutical companies, including GSK, Eli Lilly, Wyeth, Genzyme, Eisai, Pfizer, Vertex, Novartis, Proteostasis, PharmaEssentia, and Lyndra. Throughout her career, she has held positions such as Director of Biometrics, Executive Director of Clinical Operations, and Vice President. Currently, Lisa serves as a clinical consultant for Dasher Neuroscience Inc.
Commitment to
Patient-Centered Innovation
Patients are at the heart of everything we do at Dasher Neuroscience.
Our commitment to patient-centered innovation drives collaborative, cross-disciplinary research that transforms scientific discoveries into therapies addressing unmet medical needs, enhancing both treatment outcomes and quality of life.